🇺🇸 FDA
Patent

US 11479613

Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins

granted A61KA61K2039/55522A61K39/001116

Quick answer

US patent 11479613 (Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins) held by AUTOLUS LIMITED expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
AUTOLUS LIMITED
Grant date
Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/55522, A61K39/001116, A61K39/001135, A61K39/001182